Skip to content

Comparison of Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-based Pulsed-field Ablation

Comparison of Fluoroscopy-only vs. Electroanatomic Mapping Strategies for Pulmonary Vein Isolation With Balloon-based Pulsed-field Ablation

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07118046
Enrollment
96
Registered
2025-08-12
Start date
2025-08-05
Completion date
2026-03-30
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

pulmonary vein isolation, atrial fibrillation, pulsed field ablation

Brief summary

We designed a study to evaluate the impact of a two systematic strategies for PVI with the octaspline, balloon-based PFA (B-PFA) catheter. We hypothesized that the addition of electroanatomic guidance is non-superior to fluoroscopy-only guidance in achieving durable PVI.

Detailed description

Study design This is a single-center, randomized clinical study enrolling consecutive paroxysmal or persistent AF patients undergoing PVI with a B-PFA catheter (ClinicalTrials.gov identifier: pending). Patients will be randomized in a 1:1 basis to a fluoroscopy-only strategy vs. a strategy based on the same fluoroscopy workflow but with the addition of electroanatomic mapping (EAM). Procedures will be carried out under deep sedo-analgesia with propofol and fentanyl. Patients will be scheduled for systematic, invasive remapping of the left atrium (LA) and pulmonary veins (PVs) a minimum of 30 days after index ablation, regardless of recurrence status. The study will be carried out in University Hospital 12 de Octubre, a tertiary academic hospital, and has already received approval from the corresponding Institutional Review Board (code 23/208, mod. 2). Patient data will be handled according to the current General Data Protection Regulation 2016/679 of the European Parliament (EU-GDPR) and the Council of 27 April 2016 on Personal Data Protection as well as national and local regulations regarding patient autonomy, and rights and obligations in terms of information and clinical documentation. After a run-in phase of 10 cases per operator, 96 patients will be consecutively enrolled during a 4-month period (Figure 1). Randomization Patients who meet all eligibility criteria and provide informed consent will be assigned in a 1:1 ratio to one of two treatment arms: (1) PVI using fluoroscopy-only as guidance (control group) or (2) PVI guided by fluoroscopy with the addition of EAM (experimental group). Randomization will be performed electronically at each participating center via the Research Electronic Data Capture (REDCap®) platform (Vanderbilt University, Nashville, TN, USA). A computer-generated permuted block sequence, with stratification by AF presentation (paroxysmal or persistent), will be used to ensure balanced allocation. Study population Patients ≥18 years old, diagnosed with paroxysmal or persistent AF and clinical indication to undergo PVI will be included. Exclusion criteria are prior PVI or left atrial linear ablation, severe frailty or life expectancy \<1 year, unwillingness or inability to provide informed consent, ablation at sites beyond PVI or indication for additional electrophysiological study, contraindication or intolerance to heparin, presence of left atrial thrombus, congenital heart disease, and pregnancy, ongoing or planned in the following 6 months.

Interventions

DEVICEPulmonary vein isolation

Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation

Sponsors

Daniel Rodríguez Muñoz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

All events related to the dual primary efficacy outcomes and primary safety outcome will be reviewed by an independent committee. These physicians will be responsible for reviewing the acute and chronic (\>30 days) left atrial maps. Their role will be to determine PVI status and to define the type of adverse event according to its severity and relevance to the study. This committee will consist of three electrophysiologists who will not participate in the ablation or remapping procedures and who will be blinded to the characteristics of the index procedure.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥18 years old * Diagnosed with paroxysmal or persistent AF * Clinical indication to undergo PVI

Exclusion criteria

* Prior PVI or left atrial linear ablation * Severe frailty or life expectancy \<1 year * Unwillingness or inability to provide informed consent * Ablation at sites beyond PVI or indication for additional electrophysiological study * Contraindication or intolerance to heparin * Presence of left atrial thrombus * Congenital heart disease * Pregnancy, ongoing or planned in the following 6 months

Design outcomes

Primary

MeasureTime frameDescription
Durable PVI (per vein)30 days after index procedureproportion of pulmonary veins durably isolated (i.e.: more than 30 days after index procedure);
Durable PVI (per patient)30 days after index procedureproportion of patients with all pulmonary veins durably isolated (i.e.: more than 30 days after index procedure);

Secondary

MeasureTime frameDescription
Fluoroscopy exposureAt index procedurefluoroscopy time during index procedure
PFA reversibility30 days after index procedurearea of reversible electroporation, measured by comparison between acute (after index procedure) and chronic (\>30 day after index procedure) left atrial remapping

Countries

Spain

Contacts

Primary ContactDaniel Rodriguez, MD, PhD
daniel.rodriguez.mnz@gmail.com+34917792456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026